The Finnish biopharmaceutical company Medipolis GMP Ltd and the Polish pharmaceutical company Bioton SA have signed a technology licensing agreement worth EUR 5.3 million on the manufacturing technology research project of an insulin analog used in treating diabetes.
The agreement includes a technology transfer agreement regarding Medipolis GMP’s manufacturing technology research project for producing a biologically active drug, a human insulin analog. With the agreement, Medipolis GMP grants Bioton a license for using its technology for further research and development and later for manufacturing and commercial purposes.
The alternative insulin analog research by Medipolis provides diabetes care with new and more affordable alternatives. According to the latest estimates, 250 million adults worldwide have diabetes and the number is expected to increase up to 400 million by the year 2025.
Oulu Biocenter support
Medipolis GMP is based in Oulu, northern Finland, where it has a fully equipped and approved cGMP manufacturing facility specialized in biologics production. The vision of the company is to become a key player in providing technology for recombinant therapeutic proteins produced through microbial and mammalian cell culture technology.
“This is a major breakthrough for an Oulu-based biopharmaceutical company,” says Vice Rector, Professor Taina Pihlajaniemi from the University of Oulu. “The core competence of the University of Oulu Biocenter has been utilized in the development process, and Oulu’s strong medical and bioscience know-how and regional infrastructure have also supported the work well.”